Justia Intellectual Property Opinion Summaries

A non-profit organization focused on supporting student-athletes registered a stylized mark incorporating the phrase “I AM MORE THAN AN ATHLETE. GP GAME PLAN” for use in charitable fundraising via apparel sales. Later, a media company filed six intent-to-use applications for marks containing “I AM MORE THAN AN ATHLETE” and “MORE THAN AN ATHLETE,” covering clothing and entertainment services. The non-profit opposed these applications before the Trademark Trial and Appeal Board, arguing likelihood of confusion and asserting priority based on both its registration and alleged common law rights. The media company counterclaimed, seeking cancellation of the non-profit’s registration and asserting that it had acquired priority through an assignment of common law rights from a third party who had used “MORE THAN AN ATHLETE” since at least 2012.During the Board proceeding, the non-profit failed to introduce any trial evidence to establish its common law rights or priority. The Board dismissed the opposition due to lack of evidence. As to the counterclaim, the Board found that the media company had acquired valid and enforceable common law rights in the mark through its assignment, which included the goodwill associated with the mark. The Board rejected arguments that the assignment was invalid because it occurred during litigation or was an assignment in gross, and concluded that, at least for clothing, the transfer was valid. The Board canceled the non-profit’s registration and dismissed its opposition.On appeal, the United States Court of Appeals for the Federal Circuit reviewed the Board’s factual findings for substantial evidence and legal conclusions de novo. The court held that the Board’s decision was supported by substantial evidence and affirmed that the assignment was not in gross, did not violate statutory or regulatory prohibitions, and that the non-profit’s failure to submit evidence justified dismissal. The decision to cancel the non-profit’s registration and dismiss its opposition was affirmed. View "GAME PLAN, INC. v. UNINTERRUPTED IP, LLC " on Justia Law

IBM owns a patent concerning single sign-on (SSO) technology, which allows users to access protected resources on a second system using credentials from a first system. In simplified terms, the invention facilitates account creation on a second platform (such as a healthcare provider) using a user identifier already stored by the first platform (such as a social media website), thereby avoiding the need for users to create separate accounts for each service. The patent describes specific systems and processes for transmitting user identifiers and managing account creation in distributed environments.Ebates Performance Marketing, Inc. (Rakuten) filed petitions for inter partes review of IBM’s patent at the United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB), asserting anticipation and obviousness based on several prior art references, especially a system disclosed in Sunada. The PTAB adopted IBM’s construction of certain claim terms but found that Sunada taught or suggested most relevant limitations. The Board held claims 1–4, 12–16, and 18–19 unpatentable, while claims 5–11, 17, and 20 were found not unpatentable because the prior art did not disclose a specific process required by those claims.IBM appealed the PTAB’s ruling to the United States Court of Appeals for the Federal Circuit, arguing that the Board’s analysis exceeded the scope of Rakuten’s petition and that its findings lacked substantial evidence. Zillow, which had joined the review, cross-appealed regarding claims found not unpatentable. The Federal Circuit held that the Board’s analysis was consistent with the petition and supported by substantial evidence. It found the Board’s distinction between similar claims reasonable and affirmed both the appeal and cross-appeal, leaving the PTAB’s patentability determinations undisturbed. View "IBM v. ZILLOW GROUP, INC. " on Justia Law

Bayou Grande Coffee Roasting Company applied to register the trademark KAHWA for use in connection with cafés and coffee shops. The trademark examiner refused registration on the grounds that KAHWA was generic or merely descriptive, relying on two meanings: one, that KAHWA allegedly means “coffee” in Arabic, and two, that it refers to a specific type of Kashmiri green tea. The examiner also invoked the doctrine of foreign equivalents, which tests foreign words for genericness and descriptiveness by translating them into English.After Bayou responded, arguing that KAHWA does not mean coffee in Arabic and that the Kashmiri green tea meaning is not relevant to American cafés and coffee shops, the examiner maintained refusals on both grounds. Bayou requested reconsideration, and the examiner continued to refuse registration, reiterating both rationales. Bayou appealed to the United States Patent and Trademark Office’s Trademark Trial and Appeal Board, which affirmed the refusal solely on the basis of the Kashmiri green tea meaning, without addressing the Arabic coffee meaning.On further appeal to the United States Court of Appeals for the Federal Circuit, Bayou contended that the Board’s findings of genericness and mere descriptiveness were unsupported by substantial evidence, and also challenged reliance on the doctrine of foreign equivalents. The Federal Circuit held that there was no evidence showing any café or coffee shop in the United States has ever sold kahwa, and thus KAHWA cannot be generic or merely descriptive for cafés and coffee shops. The court also concluded that the doctrine of foreign equivalents does not apply because KAHWA has a well-established English meaning as Kashmiri green tea. The Federal Circuit reversed the Board’s decision, holding that KAHWA is registrable for the identified services. View "In Re BAYOU GRANDE COFFEE ROASTING CO. " on Justia Law

The plaintiffs, Coda Development s.r.o., Coda Innovations s.r.o., and Frantisek Hrabal, brought claims against Goodyear Tire & Rubber Company and Robert Benedict, alleging misappropriation of trade secrets related to self-inflating tire technology and seeking correction of inventorship on a Goodyear patent. Coda claimed that Goodyear misappropriated five specific trade secrets involving technical solutions, testing data, and optimal component placement for this technology. The alleged misappropriation stemmed from communications and interactions between the parties concerning this technology.In the United States District Court for the Northern District of Ohio, the case proceeded to a jury trial on the trade secret claims. The jury found in favor of Coda, concluding that Goodyear misappropriated five trade secrets and awarding substantial compensatory and punitive damages. Following the trial, the district court granted Goodyear’s motion for judgment as a matter of law, determining that the asserted trade secrets were either not sufficiently definite, not secret, not used by Goodyear, or not adequately conveyed to Goodyear, and thus set aside the jury’s verdict. The court also denied Coda’s claim seeking correction of inventorship on Goodyear’s patent, after considering the parties’ briefing in lieu of a bench trial.The United States Court of Appeals for the Federal Circuit reviewed the district court’s decisions. The appellate court affirmed the district court’s judgment as a matter of law, holding that no reasonable jury could have found that all elements required for trade secret misappropriation were met for any of the asserted trade secrets. The Federal Circuit also affirmed the denial of the correction of inventorship claim, concluding that Coda failed to provide evidence that would entitle it to such relief. The district court’s judgment was affirmed in all respects. View "CODA DEVELOPMENT S.R.O. v. GOODYEAR TIRE & RUBBER COMPANY" on Justia Law

Adnexus, Inc. owns a patent for a system and method of online advertising that aims to deliver targeted advertisements to users without overwhelming them with irrelevant content. Adnexus alleged that Meta Platforms, Inc.'s Lead Ads product infringed at least one claim of this patent. Specifically, Adnexus argued that Lead Ads retrieves a user profile containing delivery method preferences and other information, which matches the patent’s claim requirement. Adnexus attached detailed claim charts and a preliminary infringement analysis to its amended complaint to show how Lead Ads purportedly meets each element of the asserted claim.In the United States District Court for the Western District of Texas, Meta moved to dismiss the amended complaint, arguing that Adnexus failed to plausibly allege that Lead Ads met the claim limitation requiring retrieval of a user profile containing delivery method preferences. The district court agreed with Meta, finding that “contact information” was distinct from “delivery method preferences” and that Adnexus’s allegations were insufficient. The court dismissed the complaint with prejudice, as Adnexus had already amended its pleading once. The court also dismissed indirect and willful infringement claims, and found Adnexus estopped from asserting infringement under the doctrine of equivalents.The United States Court of Appeals for the Federal Circuit reviewed the district court’s dismissal de novo. The appellate court held that the district court erred in implicitly construing the claim term “delivery method preferences” against Adnexus, the non-moving party, without providing Adnexus an opportunity to address claim construction. The Federal Circuit found that Adnexus’s amended complaint, when taken as true and viewed in the light most favorable to Adnexus, plausibly alleged infringement of the relevant claim limitation. The Federal Circuit vacated the district court’s dismissal and remanded the case for further proceedings. View "ADNEXUS INC. v. META PLATFORMS, INC. " on Justia Law

The dispute centers on a patent for a type of cancer treatment called an antibody-drug conjugate (ADC), which combines an antibody, a cytotoxic drug, and a linker protein. The patent at issue claimed a particular kind of linker, a tetrapeptide consisting only of glycine and phenylalanine amino acids. Seagen, the patent holder, sued Daichii Sankyo and AstraZeneca, alleging that their ADC product, Enhertu, infringed claims of this patent. Notably, Enhertu contains the specific tetrapeptide sequence described in the patent. The patent’s priority was claimed from a 2004 application, though the sequence in question had not been expressly disclosed in that earlier filing.The United States District Court for the Eastern District of Texas presided over a jury trial. The jury found the asserted patent claims valid, not invalid for lack of written description or enablement, and determined that the defendants had willfully infringed. Damages exceeding $41 million were awarded to Seagen. The district court denied the defendants’ post-trial motion for judgment as a matter of law (JMOL), upholding the jury’s verdict and entering final judgment for Seagen.On appeal, the United States Court of Appeals for the Federal Circuit reviewed the case. The appellate court held that the district court erred in denying JMOL because the original 2004 application did not provide adequate written description support for the claimed subgenus of Gly/Phe-only tetrapeptides. The Federal Circuit found that the patent specification failed to demonstrate that the inventors possessed the claimed invention as of the 2004 filing date, and that the patent was not enabled because a skilled artisan would need to engage in undue experimentation to make and use the full scope of the claimed ADCs. Accordingly, the Federal Circuit reversed the district court’s judgment, found the patent invalid, and vacated the jury’s findings of infringement and damages. View "SEAGEN INC. v. DAIICHI SANKYO COMPANY, LTD. " on Justia Law

The case involves Gesture Technology Partners, LLC, which owns U.S. Patent No. 7,933,431 related to methods and apparatus for rapid TV camera and computer-based sensing of objects and human input, usable in devices such as handhelds, cars, and video games. After Samsung Electronics requested an ex parte reexamination of the patent, the United States Patent and Trademark Office initiated proceedings. Concurrently, two inter partes review (IPR) proceedings were filed against the same patent by Unified Patents LLC and other entities, resulting in the Patent Trial and Appeal Board invalidating most claims of the patent.After the Patent Trial and Appeal Board issued final written decisions in both IPRs, Gesture Technology Partners petitioned the Patent Office to terminate the ex parte reexamination, arguing that Samsung, as a party to the IPR, was estopped under 35 U.S.C. § 315(e)(1) from maintaining further proceedings on grounds that could have been raised in the IPRs. The Patent Office denied the petition, holding that the estoppel provision did not apply to ongoing ex parte reexaminations. Subsequently, the Board affirmed the examiner’s rejection of claims 11 and 13 as anticipated by a prior patent, Liebermann. Gesture appealed these decisions.The United States Court of Appeals for the Federal Circuit reviewed the case. It held that the estoppel provision of 35 U.S.C. § 315(e)(1) does not apply to ongoing ex parte reexamination proceedings, as the requester does not “maintain” the proceeding—the Patent Office does. The court also affirmed the Board’s finding that the Liebermann patent anticipates claims 11 and 13. Furthermore, it rejected the argument that the Board lacked jurisdiction because the patent had expired, citing continued rights to past damages. The court affirmed the Board’s decision as to claims 11 and 13 and dismissed the appeal as to the previously invalidated claims. View "In Re GESTURE TECHNOLOGY PARTNERS, LLC " on Justia Law

Akamai Technologies, Inc. filed suit in the United States District Court for the Central District of California seeking a declaratory judgment of noninfringement regarding two patents owned by AMHC, Inc. and its subsidiary, MediaPointe, Inc. These patents describe systems and methods for efficiently routing streamed media content over the Internet using an “intelligent distribution network.” After Akamai initiated litigation, MediaPointe counterclaimed for infringement, and Akamai further sought a declaratory judgment of invalidity.During claim construction, the district court issued an order finding that certain claims containing the terms “optimal” and “best” were invalid for indefiniteness. For the remaining asserted claims, the district court granted Akamai summary judgment of noninfringement. The court excluded key portions of MediaPointe’s expert testimony as untimely, and also found that, even considering that testimony, MediaPointe’s evidence did not create a genuine dispute regarding infringement. Specifically, the court determined that the accused Akamai system did not meet the required limitation of “receiving an initial request for media content” as understood in the context of the patents.The United States Court of Appeals for the Federal Circuit reviewed the case and affirmed both the invalidity and noninfringement judgments. The court held that the “optimal” and “best” claim terms were indefinite because the intrinsic record failed to provide objective boundaries for determining what is “optimal” or “best.” The court also concluded that, even with the excluded expert testimony included, MediaPointe had not presented sufficient evidence to create a genuine dispute of material fact regarding infringement. The Federal Circuit affirmed the district court’s judgment. View "AKAMAI TECHNOLOGIES, INC. v. MEDIAPOINTE, INC. " on Justia Law

EscapeX IP, LLC brought a patent infringement suit against Google LLC, alleging that Google’s YouTube Music product infringed its ’113 patent. After Google responded, pointing out factual deficiencies in EscapeX’s claims and highlighting that the accused features either did not exist or predated the patent, EscapeX amended its complaint to target a different Google product. Google repeatedly notified EscapeX that its claims were baseless and requested dismissal, but EscapeX did not respond. The case was transferred from the Western District of Texas to the Northern District of California. Meanwhile, a separate court found all claims of the ’113 patent ineligible under 35 U.S.C. § 101, which EscapeX did not appeal.Upon transfer, EscapeX attempted to file a joint stipulation of dismissal without Google’s consent, misstating that both parties would bear their own fees. Google demanded withdrawal, and a corrected stipulation was later filed. Google moved for attorneys’ fees under 35 U.S.C. § 285, arguing EscapeX’s claims were frivolous and that EscapeX had unreasonably prolonged litigation. The United States District Court for the Northern District of California found Google to be the prevailing party, determined EscapeX’s case was exceptional due to its lack of adequate pre-suit investigation and frivolous claims, and awarded Google attorneys’ fees and costs. EscapeX then moved to amend the judgment under Rule 59(e), presenting new declarations as “new evidence,” but the district court denied the motion, finding the evidence was not newly discovered.Google sought additional attorneys’ fees under 28 U.S.C. § 1927 for costs incurred opposing EscapeX’s Rule 59(e) motion. The district court found EscapeX’s motion frivolous and sanctioned EscapeX and its attorneys jointly and severally. On appeal, the United States Court of Appeals for the Federal Circuit affirmed all of the district court’s orders. The main holdings were that the case was exceptional under § 285, supporting an award of attorneys’ fees, and that sanctions under § 1927 for frivolous litigation conduct were appropriate. View "ESCAPEX IP, LLC v. GOOGLE LLC " on Justia Law

Duke University and Allergan Sales, LLC own a patent relating to methods for treating hair loss using certain prostaglandin F (PGF) analogs. The patent describes a method of growing hair by topically applying a composition containing a PGF analog with specific structural features. Allergan markets Latisse®, a product containing bimatoprost, a PGF analog, for eyelash hair growth. Sandoz manufactures a generic version of Latisse®. Allergan sued Sandoz for patent infringement, specifically asserting claim 30 of the patent, which covers a subgenus of PGF analogs with defined chemical characteristics.In the United States District Court for the District of Colorado, Sandoz stipulated to infringement but challenged the validity of claim 30, arguing it lacked adequate written description, was obvious, and not enabled. After a jury trial, the jury found in favor of Allergan on all grounds, concluding Sandoz had not proven invalidity and awarding damages. Sandoz moved for judgment as a matter of law and for a new trial, both of which the district court denied. Sandoz then appealed.The United States Court of Appeals for the Federal Circuit reviewed the district court’s denial of judgment as a matter of law de novo, applying Tenth Circuit standards. The Federal Circuit held that no reasonable jury could have found that claim 30 was adequately described in the patent specification. The court found that the specification broadly described billions of compounds, while claim 30 covered a much narrower subgenus, and the patent failed to provide sufficient guidance (“blaze marks”) to direct a skilled artisan to the claimed compounds. The court concluded that the written description requirement of 35 U.S.C. § 112(a) was not met and reversed the district court’s judgment, holding claim 30 invalid for lack of adequate written description. View "DUKE UNIVERSITY v. SANDOZ INC. " on Justia Law